JUNS - Jupiter Neurosciences, Inc. Common Stock

JUNS - Jupiter Neurosciences, Inc. Common Stock

https://jupiterneurosciences.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

Jupiter Neurosciences Names NBA Legend Chris Webber as Second Nugevia™ Brand Ambassador

GlobeNewswire • 3 weeks, 6 days ago • score: 0.26

Partnership expands momentum for launch of new longevity supplement line powered by clinical science and performance-driven innovation ...

Longevity In A Capsule: Jupiter Neurosciences Launches First Three Supplements Under Nugevia™ Brand - Jupiter Neurosciences ( NASDAQ:JUNS )

Benzinga • 4 weeks ago • score: 0.43

Jupiter Neurosciences Inc. JUNS, a clinical-stage pharmaceutical company developing JOTROL™ - an enhanced orally administered resveratrol formulation known for its antioxidant and anti-inflammatory effects - is solidifying its two-pronged business approach with the launch of Nugevia™, its ...

How Jupiter Neuroscience's Two-Prong Approach Could Crack The Code On Biotech Success - Jupiter Neurosciences ( NASDAQ:JUNS )

Benzinga • 3 months ago • score: 0.22

While being a biotech company can be difficult, it is not impossible. Just look at Jupiter Neurosciences Inc. JUNS, a clinical-stage pharmaceutical company, for evidence.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform products primarily for the treatment of neuroinflammation. The company is headquartered in Jupiter, Florida.

52W High

$19.51

52W Low

$0.51

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

N/A

Valuation

Source: Overview

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

N/A

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

N/A

Ownership

Source: Overview

Insiders (1–5% typical)

0.00%

Institutions (25–75% balanced)

0.00%

Shares Outstanding

31,000,000

Float

0

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Source: Overview

Revenue (TTM)

0

Gross Profit (TTM)

0

EPS (TTM)

N/A

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

N/A

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

0.0127

Previous

-0.0007

Trend

Rising

Signal Cross

Crossed Up Today

As of

Sep. 12, 2025